Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50%

被引：10
|
作者：
Zarogoulidis, Paul [1 ]
Papadopoulos, Vasilis [2 ]
Maragouli, Elena [2 ]
Papatsibas, George [2 ]
Sardeli, Chrysanthi [3 ]
Man, Yan-Gao [4 ]
Bai, Chong [5 ]
Huang, Haidong [5 ]
机构：
[1] Theageneio Canc Hosp, Pulm Dept, Oncol Unit, Thessaloniki, Greece
[2] Univ Thessaly, Dept Oncol, Larisa, Greece
[3] Aristotle Univ Thessaloniki, Fac Hlth Sci, Sch Med, Dept Pharmacol & Clin Pharmacol, Thessaloniki, Greece
[4] Vet Affair Hlth Syst, Lab Prote & Prot Sci, Baltimore, MD USA
[5] Second Mil Med Univ, Changhai Hosp, Dept Resp & Crit Care Med, Shanghai 200000, Peoples R China
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2018年 / 7卷
关键词：
SMALL BIOPSY; CASE SERIES; STAGE IV; EXPRESSION; SPECIMENS; THERAPY; SAMPLES; UPDATE;
D O I：
10.21037/tlcr.2018.01.04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S28 / S30
页数：3
相关论文
共 50 条
  • [41] Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
    Nicolazzo, Chiara
    Raimondi, Cristina
    Mancini, MariaLaura
    Caponnetto, Salvatore
    Gradilone, Angela
    Gandini, Orietta
    Mastromartino, Maria
    del Bene, Gabriella
    Prete, Alessandra
    Longo, Flavia
    Cortesi, Enrico
    Gazzaniga, Paola
    SCIENTIFIC REPORTS, 2016, 6
  • [42] Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
    Chiara Nicolazzo
    Cristina Raimondi
    MariaLaura Mancini
    Salvatore Caponnetto
    Angela Gradilone
    Orietta Gandini
    Maria Mastromartino
    Gabriella del Bene
    Alessandra Prete
    Flavia Longo
    Enrico Cortesi
    Paola Gazzaniga
    Scientific Reports, 6
  • [43] Non-small cell Lung Cancer Atezolizumab is now also approved for First-Line Monotherapy for high PD-L1 Expression
    Vetter, Christine
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (05)
  • [44] Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab
    Bureau, Mathilde
    Chatellier, Thierry
    Perennec, Tanguy
    Goronflot, Thomas
    Greilsamer, Charlotte
    Chene, Anne-Laure
    Affi, Raafet
    Frampas, Eric
    Bennouna, Jaafar
    Pons-Tostivint, Elvire
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (07) : 1747 - 1756
  • [45] Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab
    Mathilde Bureau
    Thierry Chatellier
    Tanguy Perennec
    Thomas Goronflot
    Charlotte Greilsamer
    Anne-Laure Chene
    Raafet Affi
    Eric Frampas
    Jaafar Bennouna
    Elvire Pons-Tostivint
    Cancer Immunology, Immunotherapy, 2022, 71 : 1747 - 1756
  • [46] Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status
    Alessi, Joao, V
    Ricciuti, Biagio
    Jimenez-Aguilar, Elizabeth
    Hong, Fangxin
    Wei, Zihan
    Nishino, Mizuki
    Plodkowski, Andrew J.
    Sawan, Peter
    Luo, Jia
    Rizyi, Hira
    Carter, Brett W.
    Heymach, John, V
    Altan, Mehmet
    Hellmann, Matthew
    Awad, Mark
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [47] Nivolumab plus ipilimumab as first-line treatment for patients with advanced non-small cell lung cancer: A systematic review
    Tandiono, J.
    Chen, S.
    Marcella, E.
    Susanto, B.
    Heriyanto, R. S.
    Wijovi, F.
    Tancherla, A.
    Kurniawan, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S759 - S760
  • [48] First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
    Zhou, Yixin
    Lin, Zuan
    Zhang, Xuanye
    Chen, Chen
    Zhao, Hongyun
    Hong, Shaodong
    Zhang, Li
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [49] Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
    Kuzminin, A.
    Minatta, N.
    Bluthgen, M.
    Rizzo, M.
    Naveira, M.
    Wainsztein, V.
    Lupinacci, L.
    Rizzi, M.
    Faura, M.
    Perfetti, A.
    Recondo, G., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S589 - S590
  • [50] Clinical impact of hypothyroidism and PD-L1 SNPs in patients with non-small cell lung cancer treated with nivolumab
    Yamamoto, T.
    Nomizo, T.
    Ozasa, H.
    Tsuji, T.
    Yasuda, Y.
    Yoshida, H.
    Sakamori, Y.
    Hirai, T.
    Kim, Y. H.
    ANNALS OF ONCOLOGY, 2018, 29
12345